Tumor Mutation Burden in NSCLC: Tissue Versus Liquid Biopsy Tumor Mutation Burden in NSCLC: Tissue Versus Liquid Biopsy
Tumor mutation burden may be a promising tool to guide immunotherapy, yet many questions need to be answered before adoption into clinical practice.Translational Lung Cancer Research
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
More News: Cancer | Cancer & Oncology | Health | Hematology | Immunotherapy | Lung Cancer | Non-Small Cell Lung Cancer